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Abstract
Background: Adipokines contribute directly to the atherosclerotic process, connecting metabolic disorders such as
obesity and diabetes to cardiovascular disease. Omentin-1 is a recently discovered novel adipokine, so data about
the relationship of this adipokine to vascular health in type 2 diabetes is limited.
Methods: We enrolled 60 people with type 2 diabetes, with or without carotid plaque, and 30 participants with
normal glucose tolerance. We measured serum omentin-1, high-sensitivity C-reactive protein (hsCRP) levels, and the
homeostasis model assessment of insulin resistance (HOMA-IR), as well as other cardiovascular risk factors. Vascular
health was assessed by brachial ankle pulse wave velocity (baPWV) and carotid intima-media thickness (IMT).
Results: Serum omentin-1 levels were significantly decreased in type 2 diabetes patients compared to normal
glucose controls and was further reduced in type 2 diabetes patients with carotid plaque compared to those
without carotid plaque. Multiple stepwise regression analysis showed that age, systolic blood pressure, history of
use of statins, angiotensin receptor blockers or angiotensin-converting enzyme inhibitors, and serum omentin-1
level were independent factors determining baPWV in people with type 2 diabetes (r
2 = 0.637). Furthermore, in
multivariate logistic regression analysis, circulating omentin-1 level was an independent decisive factor for the
presence of carotid plaque in type 2 diabetes patients, even after adjusting for age, gender, body mass index,
systolic blood pressure, fasting blood glucose, low density lipoprotein cholesterol, and history of smoking and
medication (odds ratio, 0.621; 95% confidence interval, 0.420-0.919; P = 0.017).
Conclusions: Circulating omentin-1 level was independently correlated with arterial stiffness and carotid plaque in
type 2 diabetes, even after adjusting for other cardiovascular risk factors and detailed medication history.
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Background
The prevalence of diabetes is expected to rapidly increase
from 171 million individuals (2.8% of the world’s popula-
tion) in 2000 to 366 million (4.4% of the world’s popula-
tion) by 2030 [1]. Individuals with diabetes have two- to
three-fold increased risk of myocardial infarction or stroke
compared to individuals without diabetes [2]. However,
the underlying mechanisms linking type 2 diabetes with
cardiovascular disease remain poorly understood. Recent
evidence has shown that some adipokines are major regu-
lators of insulin resistance and direct mediators of
endothelial dysfunction and macrophage infiltration of
vessel walls [3]. The identification of a novel adipokine
involved in the atherosclerotic process might provide new
opportunities for preventing cardiovascular disease in
patients with type 2 diabetes.
Omentin is a novel fat depot-specific adipokine that was
identified in 2003 from a visceral omental adipose tissue
cDNA library [4]. The omentin gene is located in the
1q22-q23 chromosomal region, which has been linked to
type 2 diabetes in several populations [5,6], suggesting that
omentin may be a candidate gene for type 2 diabetes
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any medium, provided the original work is properly cited.susceptibility in humans. In fact, Yang et al. [7] demon-
strated that recombinant omentin-1 enhances insulin-
stimulated glucose uptake and Akt phosphorylation in
human adipocytes. Several clinical studies have shown that
the serum omentin-1 level is significantly decreased in
obese patients or patients with polycystic ovary syndrome
or diabetes [8-10]. In addition, circulating omentin-1 levels
are negatively correlated with metabolic risk factors,
including body mass index, waist circumference, and insu-
lin resistance [8-10].
Recent clinical studies have focused on the influence of
the novel adipokine omentin-1 on vascular health
[11-14]. In these studies, circulating omentin-1 had a
negative correlation with atherosclerotic parameters.
However, no previous studies have clarified the relation-
ship of serum omentin-1 with atherosclerosis in subjects
with type 2 diabetes. Carotid intima-media thickness
(IMT) and arterial stiffness are useful surrogate markers
for subclinical atherosclerosis and are significantly corre-
lated with various metabolic risk factors [15,16]. In pro-
spective studies, both arterial stiffness and carotid IMT
have proven to be consistent and independent predictors
for cardiovascular events [17]. Recently, Dall Pozza et al.
[18] showed that longitudinal carotid IMT is indicative of
disease progression during a four year period, even in
adolescents with type 1 diabetes, and that brachial ankle
pulse wave velocity (baPWV) is a non-invasive method
for quickly measuring arterial stiffness that is not influ-
enced by operator technique [19].
Therefore, in this study, we determined the relationship
of circulating omentin-1 levels with atherosclerosis, as
measured by carotid IMT and baPWV, in subjects with
type 2 diabetes and controls. Furthermore, to determine
the exact correlation of circulating level of omentin-1 with
baPWV and carotid IMT in type 2 diabetes, we adjusted
for other cardiovascular risk factors and detailed drug his-
tory that could affect vascular function.
Methods
Study design and participants
The study subjects were 30 people with type 2 diabetes
without carotid plaque, 30 people with type 2 diabetes
with carotid plaque, and 30 control participants with nor-
mal glucose tolerance. Diabetes was defined as a fasting
plasma glucose value ≥ 7.0 mmol/L (126 mg/dL) or a
previous diagnosis of diabetes. All were self-referred
from the Department of Endocrinology and Metabolism
at Korea University Guro Hospital. All subjects in the
control group were administered a 75-g oral glucose
loading test to exclude subjects with pre-diabetes or
undiagnosed diabetes using the criteria of the American
Diabetes Association [20]. The study exclusion criteria
included histories of cardiovascular diseases (myocardial
infarction, unstable angina, stroke, peripheral artery
disease, or cardiovascular revascularization), stage 2
hypertension (resting blood pressure ≥ 160/100 mmHg),
uncontrolled diabetes mellitus (HaA1c > 10%), malig-
nancy, or severe renal or hepatic disease. We also
excluded patients with inflammatory conditions such as
vasculitis or aortitis, or acute infectious disease. We
investigated smoking and medication histories including
use of insulin, oral hypoglycemic agents, statins, anti-pla-
telet agents, angiotensin receptor blocker (ARB), angio-
tensin-converting enzyme (ACE) inhibitors or calcium
channel blockers. All participants provided written
informed consent, and the Korea University Institutional
Review Board, in accordance with the Declaration of Hel-
sinki of the World Medical Association, approved the
study protocol.
Clinical and laboratory measurements
Body mass index (BMI) was calculated as weight/height
2
(kg/m
2)a n dw a i s tc i r c u m f e r e n c ew a sm e a s u r e da tt h e
midpoint between the lower border of the rib cage and
the iliac crest. All blood samples were obtained the
morning after a 12-hour overnight fast, and were imme-
diately stored at -80°C. Serum triglycerides and high-den-
sity lipoprotein-cholesterol (HDL-C) were determined
enzymatically using a chemical analyzer (Hitachi 747;
Hitachi Inc., Tokyo, Japan). Low-density lipoprotein
(LDL)-cholesterol concentration was estimated using the
Friedewald formula [21]. The glucose oxidase method
was used to measure plasma glucose and an electroche-
miluminescence immunoassay (Roche Diagnostics, India-
napolis, IN, USA) was used to measure insulin levels.
Insulin resistance was calculated by the homeostasis
model assessment of insulin resistance (HOMA-IR).
hsCRP levels were measured by latex-enhanced turbidi-
metric immunoassay (HiSens hsCRP LTIA, HBI Co.,
Ltd.), with an interassay coefficient of variation of 7.2%.
Serum concentrations of omentin-1 were determined by
an enzyme-linked immunosorbent assay (ELISA) kit
(Apotech, Axxora, Nottingham, UK); intra- and inter-
assay variations were 3.6 ± 0.7% and 4.6 ± 0.3%,
respectively.
Measurement of baPWV
After subjects rested in the supine position for 5 min-
utes, baPWV was measured using a volume-plethysmo-
graphic apparatus (model BP-203RPE II; Colin, Komaki,
Japan) that simultaneously recorded baPWV and bra-
chial and ankle blood pressures on the left and right
sides. The details of this method, including validity and
reproducibility, were described previously by Yamashina
et al. [22]. The intra- and inter-observer reproducibility
of this method in the present study were 10.0% and
8.4%, respectively. The baPWV was calculated as the
mean of the left and right baPWV values.
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The IMT of the common carotid artery was determined
using high-resolution B-mode ultrasonography (EnVisor;
Philips Medical Systems, Andover, MA, USA) with a 5-
12 MHz transducer. Carotid plaque was defined as a
focal structure protruding into the arterial lumen with a
thickness ≥ 1 . 3m m[ 2 3 ] .M e a s u r e m e n t so ft h ec a r o t i d
IMT were made using IMT measurement software (Inti-
mascope; Media Cross Co., Tokyo, Japan) at three levels
of the lateral and medial walls of the carotid artery, 1-3
cm proximal to the carotid bifurcation. The maximal
IMT was the value at the maximal point of the region.
Carotid IMT was calculated as the mean of the maximal
left and right IMT values. All measurements were
recorded by a single trained technician who was blinded
to the anthropometric and laboratory data.
Statistical analysis
Each variable was examined for normal distribution by the
Kolmogorov-Smirnov equality of distributions test. Data
are expressed as the mean with standard deviations (SDs)
or median (interquartile range, 25%-75%), or as a percen-
tage. Differences among the groups were tested using
ANOVA for normally distributed variables or the Kruskal-
Wallis H test for non-normally distributed variables, and
Fisher’s exact test or Pearson’s chi-square test for categori-
cal variables. Subsequent pair-wise comparisons were per-
formed by Tukey’s HSD post hoc analysis or the Wilcoxon
rank-sum test. Analysis of covariance (ANCOVA) was
used to compare the mean baPWV values according to ter-
tile of serum omentin-1 level after adjusting for known
covariates. Multiple linear stepwise regression analysis with
baPWV as a dependent variable was performed to identify
the risk factors that determined baPWV in type 2 diabetes.
Subsequently, age, gender, BMI, systolic blood pressure,
fasting blood glucose, smoking and medication history,
including usage of statins and ARB or ACE-inhibitors, and
circulating omentin-1 level, were used as independents
variables. Unadjusted and adjusted odds ratios (ORs) with
95% confidence intervals (CIs) predicting carotid plaque in
type 2 diabetes patients based on circulating omentin-1
level were generated using univariate and multivariate
logistic regression analyses after controlling for other
potential covariates. All statistical results were based on 2-
sided tests. Data were analyzed using SPSS for Windows
(version 12.0; SPSS Inc., Chicago, IL, USA). We regarded a
P value of less than 0.05 as statistically meaningful.
Results
Characteristics of study subjects
The clinical and biochemical characteristics of the study
subjects are in Table 1. Although there were no signifi-
cant differences in age, gender or BMI, significant differ-
ences between groups were seen in waist circumference,
systolic blood pressure, fasting blood glucose, HOMA-IR,
and history of medication use including statins, anti-
hypertensive agents, and anti-platelet agents (Table 1). In
particular, baPWV values showed an increasing trend in
subjects with normal glucose tolerance, those with type 2
diabetes without plaque and those with type 2 diabetes
with plaque. In addition, circulating omentin-1 levels
were significantly decreased in type 2 diabetes patients
compared to normal glucose controls and were further
reduced in type 2 diabetes patients with carotid plaque
compared to those without carotid plaque (Figure 1).
Arterial stiffness stratified by the tertile of serum
omentin-1 level in type 2 diabetes
Subjects with the highest tertile serum levels of omentin-1
(T3) exhibited the most significant detrimental signs of
baPWV compared to those in tertile serum omentin-1
groups T2 or T1 after adjusting for age, gender, and BMI
(Figure 2, Model 1). Further, after adjusting for other con-
founding factors such as systolic blood pressure, smoking,
and drug history (i.e., usage of statins or ARB or ACE inhi-
bitors), arterial stiffness was significantly associated with
increased level of serum omentin-1 (P for trends = 0.023;
Figure 2, Model 2). Based on the results of multiple linear
regression analyses, age (P < 0.001), systolic blood pressure
(P < 0.001), medication history including statin (P = 0.007)
and ARB or ACE inhibitor (P = 0.013) and serum omen-
tin-1 level (P = 0.023) were independent determining fac-
tors for mean baPWV (R
2 = 0.637)
Odds ratio of serum omentin-1 level predicting carotid
plaque in type 2 diabetes
According to univariate and multivariate logistic regres-
sion analyses, the ORs of carotid plaque according to
serum omentin-1 level are displayed in Table 2. Interest-
ingly, the OR for carotid plaque was 0.692 (95% CI,
0.510-0.938) according to the increased level of serum
omentin-1 based on an unadjusted model. The adjusted
ORs for carotid plaques in the first, second, third and
fourth models were 0.672 (95% CI, 0.478~0.944), 0.650
(95% CI, 0.454~0.930), 0.649 (95% CI, 0.438~0.962),
0.621 (95% CI, 0.420~0.919), respectively. Most impor-
tantly, inclusion of confounding factors which can affect
carotid atherosclerosis did not alter the results of our
multiple regression analyses.
Discussion
We demonstrated that serum omentin-1 levels were sig-
nificantly decreased in type 2 diabetes patients com-
pared to normal glucose controls, and were further
reduced in type 2 diabetes patients with carotid plaque
compared to those without carotid plaque. Furthermore,
the circulating omentin-1 value was an independent
determining factor for arterial stiffness and the existence
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after adjusting for confounding cardiovascular risk fac-
tors and detailed medication history.
Adipokines and atherosclerosis
The adipose tissues of individuals with type 2 diabetes
secrete pro-inflammatory adipokines that contribute to
the initiation of insulin resistance [24]. Some adipokines,
such as resistin, leptin, and adiponectin directly mediate
vascular health by influencing the function of endothelial
cells, arterial smooth muscle cells, and macrophages in the
vessel wall [3]. Recently, we reported that serum resistin
and adipocyte fatty acid-binding protein are independently
associated with atherosclerotic inflammation, as deter-
mined by [
18F]-fluorodeoxyglucose positron emission
tomography [25,26]. The production of adipokines by adi-
pose tissue is an important mechanism for the adverse
effects of adiposity on cardiovascular disease [27].
Relationship of the novel adipokine omentin-1 with
vascular health: Clinical studies
Omentin, which is highly and selectively expressed in visc-
eral adipose tissue, has been suggested to be an anti-
inflammatory molecule [28] and is thus assumed to have
paracrine and autocrine roles in improving insulin sensi-
tivity [7]. In 2011, several clinical studies examined the
relationship between circulating omentin-1 with vascular
health. Moreno-Navarrete et al. [11] demonstrated that
the circulating omentin-1 concentration contributes inde-
pendently to endothelial dysfunction even after controlling
for adiposity, age, and inflammation in subjects with
impaired glucose tolerance. In that study, vascular reactiv-
ity was measured by high-resolution ultrasound of the bra-
chial artery. Since then, two other reports on the negative
correlation of serum omentin-1 with carotid IMT have
suggested an cardioprotective and anti-atherosclerotic role
of omentin-1 [12,14]. Liu et al. [12] demonstrated that
Table 1 Baseline characteristics of study subjects
Normal glucose tolerance Type 2 diabetes Type 2 diabetes P-value
without carotid plaque with carotid plaque
(N = 30) (N = 30) (N = 30)
Age (years) 54.07 ± 8.14 53.1 ± 6.81 56.47 ± 6.04 0.169
Gender (M:F) 12 : 18 10 : 20 15 : 15 0.418
BMI (kg/m
2) 23.99 ± 2.88 23.89 ± 2.29 24.18 ± 2.11 0.895
Waist circumference (cm) 85.19 ± 6.05
a 93.68 ± 6.76
b 95.12 ± 3.98
b < 0.001
SBP (mmHg) 119.67 ± 12.73
a 119.33 ± 10.56
a 129.83 ± 17.95
b 0.007
DBP (mmHg) 77.67 ± 10.06 74.5 ± 8.55 77.72 ± 9.92 0.332
Fasting blood glucose (mmol/L) 5.16 ± 0.55
a 7.06 ± 2.06
b 7.28 ± 1.53
b < 0.001
HOMA_IR 1.66 (0.92, 2.52)
a 2.7 (1.91, 4.10)
b 2.96 (1.92, 3.86)
b 0.002
HbA1c 5.68 ± 0.34
a 7.27 ± 1.04
b 7.4 ± 0.94
b < 0.001
LDL cholesterol (mmol/L) 2.58 ± 0.81 2.28 ± 0.60 2.27 ± 0.50 0.122
HDL cholesterol (mmol/L) 1.41 ± 0.39 1.24 ± 0.34 1.29 ± 0.27 0.159
Triglyceride (mmol/L) 1.02 (0.70, 1.56) 1.17 (0.98, 2.29) 1.36 (1.02, 1.68) 0.057
hsCRP (mg/dL) 0.56 (0.34, 1.45) 0.57 (0.35, 1.21) 0.45 (0.30, 1.13) 0.428
Carotid IMT (cm) 0.84 ± 0.11
a 0.86 ± 0.12
a 0.98 ± 0.16
b < 0.001
baPWV (m/sec) 13.26 ± 1.77
a 14.29 ± 2.57
a 16.22 ± 3.07
b < 0.001
Current smoker (%) 26.77 30 46.67 0.218
Statin (%) 10.00
a 33.33
ab 40.44
b 0.024
Anti-platelet agent (%) 6.67 6.67 26.67 0.031
ARB or ACE inhibitor (%) 10.00
a 16.67
ab 40.00
b 0.013
Calcium channel blocker (%) 10 13.33 20 0.533
Insulin (%) - 13.33 16.66 0.718
Sulfonylurea (%) - 33.33 43.33 0.426
Glucophage (%) - 53.33 56.66 0.795
Thiazolidinedione (%) - 10 13.33 0.688
Duration of diabetes (years) - 8.47 ± 5.46 12.17 ± 7.35 < 0.001
Data are expressed as the mean with SD, median (inter-quartile range), or percentage. P-value for overall difference among the groups was calculated from the
analysis of variance (ANOVA), the Kruskal-Wallis H test, or Pearson’s chi-square test. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; HOMA-IR, homeostasis model assessment of insulin resistance; LDL, low-density lipoprotein; HDL, high-density lipoproteins; hsCRP, high sensitivity C-
reactive protein; IMT, intima-media thickness; baPWV, brachial ankle pulse wave velocity; ARB, angiotensin receptor blocker; ACE, angiotensin-converting enzyme
inhibitor.
a, b, c: same letter indicates no statistical difference between the groups based on post hoc analysis.
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carotid IMT in metabolic syndrome patients and Shibata
et al. [14] showed similar results in apparently healthy
men. However, no studies have investigated the impact of
serum omentin-1 level on atherosclerosis in type 2 dia-
betes. Recently, El-Mesallamy et al. [29] examined the cir-
culating level of omentin-1 in an Egyptian population with
type 2 diabetes, with and without ischemic heart disease.
Although they did not detect clear differences in serum
omentin-1 levels between type 2 diabetes patient with and
without ischemic heart disease, multiple regression analy-
sis showed that IL-6 level was an independent risk factor
influencing serum omentin-1 level. This suggests that
omentin-1 is regulated by inflammation. Inflammation is
the most important factor linking type 2 diabetes to the
progression of cardiovascular complication. Recently,
Zhong et al. [13] demonstrated that serum omentin-1
levels were lower in patients with acute coronary syn-
drome or stable angina pectoris compared to controls. We
showed that even after controlling for other risk factors
and drug history that could affect vascular function, serum
omentin-1 level was independently associated with arterial
stiffness and carotid plaque. Previous studies and our
results suggest that circulating omentin-1 might mediate
not only the insulin signaling pathway but also directly
affect the anti-atherosclerotic process.
Underlying mechanisms of omentin-1 and atherosclerosis:
Experimental studies
Recently, several in vitro studies have been published
that could explain the underlying mechanism of the
connection between circulating omentin-1 and the
atherosclerotic process. Yamawaki et al. [30] found that,
in the isolated rat aorta, omentin directly induces an
endothelium-dependent relaxation that is caused by
n i t r i co x i d ep r o d u c e db yt h ee n d o t h e l i u m .T h es a m e
group [31] also showed that omentin inhibits TNF-a
induced COX-2 expression by inhibiting the JNK signal-
ing pathway in human umbilical vein endothelial cells,
suggesting that omentin might prevent atherosclerosis
by modulating the vascular endothelial inflammatory
state. Furthermore, Xie et al. [32] reported that adeno-
virus-mediated overexpression of omentin-1 attenuated
arterial calcification in OPG
-/- mice, suggesting that
increasing concentrations of omentin-1 may be benefi-
cial for protecting arteries.
Figure 1 Serum omentin-1 levels in normal glucose tolerance group, type 2 diabetes patients without carotid plaque and type 2
diabetic patients with carotid plaque.
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The principal limitation of our study was its cross-
sectional design. We cannot identify whether increased
circulating omentin-1 had a direct impact on arterial
stiffness and carotid plaque or was a consequence of
increased arterial stiffness and arterial wall thickness.
Therefore, we are planning a longitudinal study of the
relationship of circulating omentin-1 levels with changes
in baPWV and carotid plaque in people with newly diag-
nosed type 2 diabetes. Second, we enrolled only a limited
sample, so the relationship between circulating omentin-
1 and atherosclerosis in type 2 diabetes should be further
examined in a prospective design with a larger number of
subjects. Lastly, although recent reports have demon-
strated a close relationship between serum omentin and
adiponectin levels, and that the regulation of omentin
might be dependent on adiponectin [33], we did not
measure adiponectin level. Further studies examining the
influence of the relationship between omentin and adipo-
nectin levels on cardiovascular disease would be
interesting.
Conclusions
In conclusion, this study showed that the circulating
omentin-1 level is significantly decreased in type 2 dia-
betes patients compared with control subjects and further
decreased in subjects with carotid plaque. We demon-
strated that serum omentin-1 level was independently
associated with arterial stiffness and the presence of caro-
tid plaque, even after adjusting for other cardiovascular
risk factors and medication history. Additional experimen-
tal studies and large-scale prospective clinical studies are
Figure 2 Mean values of brachial ankle pulse wave velocity (baPWV) based on the tertile of serum omentin-1 level in type 2 diabetes
(N = 60). T1: lowest tertile of serum omentin-1, T2: median tertile of serum omentin-1, T3: highest tertile of serum omentin-1. Model 1: adjusted
for age, gender and body mass index. Model 2: adjusted for age, gender, body mass index, systolic blood pressure, smoking and medication
history including statins, angiotensin receptor blockers, or angiotensin-converting enzyme inhibitors.
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sclerotic process in people with type 2 diabetes.
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